<SEC-DOCUMENT>0001075880-12-000065.txt : 20120925
<SEC-HEADER>0001075880-12-000065.hdr.sgml : 20120925
<ACCEPTANCE-DATETIME>20120924183946
ACCESSION NUMBER:		0001075880-12-000065
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120925
FILED AS OF DATE:		20120925
DATE AS OF CHANGE:		20120924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		121107495

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20120924.htm
<DESCRIPTION>FORM 6K 2012 09 24
<TEXT>
<html>
<head>
    <title>form6k20120924.htm</title>
    <!--Licensed to: Novogen Laboratories-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5%; FONT-SIZE: 14pt; MARGIN-RIGHT: 5%">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">For the month of September, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Commission File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">140 Wicks Road, North Ryde, NSW, Australia</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive office)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Form 20-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf </font>by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">/s/&#160;&#160;Ron Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Ronald Lea Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Company Secretary</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Date 25 September, 2012</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right">
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><img src="novogenlogo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">ASX &amp; MEDIA RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">24 SEPTEMBER, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">NOVOGEN ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH KAI MEDICAL</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Novogen Limited today announced the termination of its previously announced merger agreement with Kai Medical.&#160;&#160;Under the terms of the merger agreement entered into by the companies, the merger agreement shall forthwith become void and have no effect without any liability or obligation on the part of Novogen or Kai.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">In making the announcement, William D Rueckert, Chairman stated:&#160;&#160;&#8220;this is a disappointing outcome for our Company.&#160;&#160;We were enthusiastic about the prospects for future value creation through Kai&#8217;s business plan and product development.&#160;&#160;However, the details of the transaction made it impossible to insure the continued listing of Novogen&#8217;s securities on the ASX and Nasdaq markets.&#160;&#160;In making the decision, the Novogen Board agreed that it is an imperative that it maintains the listings and liquidity in the Company&#8217;s shares.&#160;&#160;The Company will continue to explore transactions that it believes will enhance shareholder value including a possible capital reduction and in specie distribution of MEI Pharma shares to the Novogen shareholders.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">About Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc.&#160;&#160;More information on the Novogen group of companies can be found at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.novogen.com</font>.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenlogo.jpg
<TEXT>
begin 644 novogenlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!"`,\#`2(``A$!`Q$!_\0`
M'``!`0$!`0`#`0````````````<&!0@!`P0"_\0`1A```0,#`@,&`@4'"`L`
M`````0`"`P0%$08A!Q)!$R(Q46&!%'$(%3*1H187(S1T@K$S.%)RL\'1X4)&
M5%9B=9*3HL+2_\0`&@$!``,!`0$```````````````(#!`$%!O_$`#(1``$#
M`@4"!`4"!P````````$``A$#!!(3(3%!47$%%(&A(C)2D<%AL2,S0D/1X?'_
MV@`,`P$``A$#$0`_`/5*(B(B(B(B(B(B^BKJ8Z5L3I7!H?(V,$]2XX`^_"^]
M8OC#/4TG#ZXU=$XMJ*9\,['#H6RL.?P70),*%1^!A=T"VB+/Z$U12:NT[3W.
MD+0]PY9X0<F*0>+3_$>8(6@0B-"NM<'@.;L41$7%)$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$12'B%Q%O.FM;/H:6*GEM\,<4TC'1DN+3]KO`[;*#WA@DK1;6S[
ME^73W5>1?DM-PI[K;*6OHG\]-41B1A]".OJL;Q8U5<M+TUIDM?89J:GLY.U9
MS=W;PW]5US@T8BH4J+ZM3+;NMZB*8ZLXBUIOCK!HJ@;<KFUQ9)*X]QCAX@#;
M..I)`'JCGANZ[0MWUS#!MOT`_54Y9SB/1FOT%?Z=K>9SJ.1S1ZM;S#\0L74#
MBQ14YJ^VM-86CF=2L8.;'C@;#/EL5VM`:^IM7"HM=RI307B-KFS4S_!X&SN7
M.^W5IW'JN-JC$`=%.M8ORW.:0X<P9A><>'FLJW1E\;64N9*63#*FG)P)69_!
MPZ'_`!*]=V"\45^M%-<K9*):6H;S-/4>;2.A!V(\UXOU/:I+'J&XVR7/-2SN
MC!/4`['W&"J)]'_6#[-J,66KEQ;KB[#`X[1S?Z)'];[)_=\EOK,#AB"^3\-N
MG4:F0_8^Q7IQ$6%L>J+A>>)5WM5*8#9;;&&R.#,N=+L,<W3?FV_X5B+@%]/3
MI.J!Q'`DK=(IQKOB.^UW9MATS0_6E\<>4M`)9&<9Q@;DXW/0=3T7X#'Q9%*:
MKXBTN>!GX4-;S'TSC&?=0-43`U6AMD\M#GD-G:3$JK(I[H'B$^\W*2R:AH?J
MR^1DM[,YY92!D@`^!QOC)SYJA.(:"7$`#<D]%)K@X2%16H/H.PO"(I5=.(MW
MOEVGM?#VV-KG0Y;+6S?R;3G`(W`QL=R=_)?$C.+-,P3MEM%6?$T[6M&/3)`^
M7BH9HX$K1Y%X'QN#3T)U5619_0UQO5SLG;ZDMK;=7-E='V;2>\T>#L;XSOU/
MGU66XA:GU'0:QM5CTTVD=+64YD`G;XN#CUSL,!2+P!B*J9;/?4-,$2)YTT_5
M4E%+^UXK?[/9?^L+>Z:=='62E.H&0,NG*>W;`<LSD^'MA=:Z>%RK0RQ.('L5
MTT46TQQ5N#]7?!7YM.+;+4/I62QQEIC?S$,R<XQMO\\JTKC'A^H7;BUJ6Q`J
M<B418&35=Q;Q?BTV.Q^K7TW:GN=_FY"?'/F%OE(.!V5=2DZG&+D2BC-YH:>Y
M<?Q15L39::>W.CD8[P(,3E9E(I_YQU/^PG^S<JZO'=:;$D%Y'TE?/#6NGTAJ
MNNT5>)3V+W&:W2/.S@23@'U&^/,.7]?2#_4=/_MG_P`KL\8M+R7BRQW:V!S;
MQ:LSPN9]IS1@D#&^1C(]1ZK`\0=3,U9HO3%P#>2H;6]E41_T)!RY]CXCYJI_
MPM+#Z+T;89]9ERW?4.[P=?7]U7^(%TDLNC+O7P9$L4!#"#@ASNZ#[9S[+,<"
M['#;]'Q7-S>:LN)=*Z1P[P9G`;GVSZDK0<3;?)<]!WFF@`,I@[1H]6D.V]=E
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MIIN7]1%0YH.`9.7=H_>V64X602V+AM=-0U>375@FKG.D))(:#RY^9!/NIS8[
MK-=^&%ATG2/'Q%9<WP.V^S&"'[^F7Y_=7H&]6ELND*VTT3.5AHGT\3&[8[F&
MC^"P5!_$,<+ZVU>!9TR_^X03V'^Y^RGW`&SAULKM15K"^X5LSF"5^[N48+CG
MU=G[E6E+^`%U94Z4GMLCP*JBG<3&1@ACMQ\]^8*H+E",`A6>)EWFGAW7VX]E
M(>/EL;1TUMU/1?HJZDG;&Y[-BX>+22/(MQ\B0NOQ6U%)!PPCJ:?FCFNC(HQR
MG!:'MYG;_P!4$>ZY_P!(2XQBP4%FC<365M2U[6MW(:WK[N+0%]O%RQS#A521
MM([6UB%[R/#`;R./_EGV5;Y!?AZ+9;PYMOG;8C';_JU7#6PPZ?T?;Z:)@;-+
M&V>=W5TC@"?NV'LM0L]P_O,%]TC;:N!P+A$V*5N<EDC0`X'W_`A:"0D,<1X@
M%7LC"(V7E7!>:KLS>3*^5)M>5E-;^,^EJJMF9!3QTC^>20X:W)>-S\RNQP7U
M#<]1V"OJ;Q4_$31U;HV'D:WE;R@XV`\UQ.(5NI+MQBTQ0W&!L])-2/#XW9P[
M!>>GJ`J7NQL#AU6^VHY%P^G4X:Z8[<+>MUGIIS@UM]MQ).`!.W_%=]8]G#31
M['M>VQTX<TAP/._8@Y!^TM@KFXOZEAK9.F3/K'X4`T9I>/5>F-9T8:/C&7!T
ME*_P+9!G`SY'P/\`DJ%PAU1)?+));[F[%YMKNPJ&.V<YHV#B#]Q]1ZKB\!?]
M:_\`F)_O7T\1:*HT9K"DUM:8'/II7"&XQ,SN#MS>^W[P!ZJAOP@/'JO3JG/J
M/MG;[M[QMZ_ND_\`..I_V$_V;E75&Z>KAK_I`V^KI7B2GGMPDC<.K3$2%9%9
M2Y[K%>@C+!^D?E%-9;%<W<<X;P*.3ZL;1\AJ-N7FY",?>52D4W-Q0L]*J:4Q
MR"/NB\^<1.']RH-4A^GJ"KJ;75S,J3'`WF;"_F[P(Z#J/0D=%Z#11J4Q4$%7
M6=X^T>7,UGA#N,'P4AO6CM0Z2U#-?-`\L]+.>:HMSSX[Y(`/B/'&.\,E5Y%U
M[`[=5T+AU`G#J#N#L5)GZ]UO5,%-1:(GAK=@Z2;F[,$]=P/XKH\/M!5M#>)=
M1ZKJ6U=\F&0T8+8B1@G/@3C88V`\%2$413UEQE7.O(:64FAH.\;_`'/"+F:E
ML=%J*S5-LN<0DIYFX]6.Z.!Z$+IHK=EA(#A!4%X,:#K[+Q!NLETIY1!;0603
M.9ADSG9`<WS[N3MX9"O2(AU)/5&RUC:?#1`[3/Y4JU;H6[VW4;]3:%F9'6/.
M9Z-Q`$F3EV,[8.,D'KN"OK_.!K7LC3_D+4_'X^WW^S\?+'_LJRBJRX/PF%O%
M[B:!68'1L3,^VZE>C-#7:OU`-3:\E;-<&D.IZ5I!;$1X$XV&.@'4Y.ZJ,\,=
M1!)#.QLD4C2Q['#(<#L05_:*;6!H@*BO</KNQ.XV'`[*-R:0U5H.YS5>B'MN
M%KE)<^AE.X'08SN1T(P?1?K;Q"UC-$Z%FA*OXD=TEW.&Y]V_WJLHH"EA^4PM
M!O14UK,#CUU!]8W4_P""^G;EIS3E5!>*<4\\]296Q\X<0WE`WQ\ER^)-!J"+
MB!9+Y8+0^XBCIG-(R`WF+G9!W'1RJB+N4,(:H>=>:SJY`DSVUT4L_*_B'_N0
MS_O?YK>Z6K;E<+)!47JA%!7.+N>G!SRX)QO\L+K(I!I'*IJ50\0&`=I_RIQP
M<LMRLYU&+G1RTPGKC)$7X[[=]QNMW>+;37BUU5OKH^TIJAAC>WT/4>H\5^Q$
M:T`0E2LZI4S-BH1P\TA>[#Q1IVUE'5OM](R:*.L<W]&6<IY,'IG/AYY5W1%R
MG3#!`5EW=NNGA[QJ!"(B*:RHB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
+B(B(B(B(B(B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
